| NCT ID | NCT06103136 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Moon Surgical |
| Condition | Surgery |
| Study Type | OBSERVATIONAL |
| Enrollment | 600 participants |
| Start Date | 2023-09-29 |
| Primary Completion | 2027-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 600 participants in total. It began in 2023-09-29 with a primary completion date of 2027-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of the study is to observe the real-life usage of the Maestro Platform for surgical assistance in laparoscopic surgery.
Eligibility Criteria
Inclusion Criteria: * Participants will be adults aged ≥ 18 years scheduled for laparoscopic surgery. Exclusion Criteria: * Participants might be excluded based on the investigator's discretion.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06103136 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Surgery. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06103136 currently recruiting?
Yes, NCT06103136 is actively recruiting participants. Contact the research team at aosdoit@moonsurgical.com for enrollment information.
Where is the NCT06103136 trial being conducted?
This trial is being conducted at Denver, United States, Fort Myers, United States, Jacksonville, United States, Jacksonville, United States and 8 additional locations.
Who is sponsoring the NCT06103136 clinical trial?
NCT06103136 is sponsored by Moon Surgical. The trial plans to enroll 600 participants.